as 05-30-2025 3:36pm EST
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Founded: | 1999 | Country: | France |
Employees: | N/A | City: | N/A |
Market Cap: | 209.2M | IPO Year: | 2019 |
Target Price: | $13.00 | AVG Volume (30 days): | 10.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.03 | EPS Growth: | N/A |
52 Week Low/High: | $2.55 - $6.42 | Next Earning Date: | 04-24-2025 |
Revenue: | $73,187,701 | Revenue Growth: | 105.01% |
Revenue Growth (this year): | 15.98% | Revenue Growth (next year): | -38.13% |
GNFT Breaking Stock News: Dive into GNFT Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
MT Newswires
12 days ago
GlobeNewswire
12 days ago
GlobeNewswire
18 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "GNFT GENFIT S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.